131 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
1 Dec 20
Other Events
7:46am
Patients (p<0.0001) –
– Safety Profile Consistent with Previously Reported Data –
– Topline Data from the Mitapivat Phase 3 ACTIVATE-T Trial … a statistically significant, sustained increase in hemoglobin compared to placebo. The safety profile observed in the study was generally consistent
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
4 Sep 19
Other Events
5:05pm
Treatment Duration of 28.9 Months –
– Cumulative Safety Profile (Core Period plus Extension Phase) Continues to Support Long-term Twice Daily Dosing … evaluating the safety and efficacy of mitapivat in adults with PK deficiency in our ongoing Phase 3 ACTIVATE andACTIVATE-T studies, and we look forward
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
16 Jun 14
Other Events
12:00am
on AG-221’s clinical activity, safety profile and unique mechanism of action. The data were presented today in a late-breaker oral presentation … with substantial reductions in plasma levels of the oncometabolite 2-hydroxyglutarate (2HG). Safety data show that AG-221 is well tolerated, with the majority
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
7 Dec 20
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
4:53pm
and Increased ATP –
– Safety Profile Generally Consistent with Previously Presented Data in Patients with Pyruvate Kinase Deficiency and Thalassemia … mitapivat may be a promising sickle cell disease treatment option with a well-tolerated safety profile and convenient oral administration. I look
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
activation in healthy volunteers, providing an opportunity to understand the safety, dosing and pharmacodynamic activity of AG-348 prior to entering … safety results are being reported from the SAD Phase 1 study and showed that AG-348 was well tolerated. Although the MAD study remains blinded
8-K
EX-99.2
0eaqw70etngq
16 Oct 15
Regulation FD Disclosure
12:00am
8-K
EX-99.1
ksi0ev4 fxw2t1wy
11 Jun 21
Other Events
7:24am
8-K
EX-99.1
u1f6 1n0aa7
16 Nov 18
Agios Presents Updated Data from Phase 1 Dose-Escalation Study ofAG-881 in Patients with IDH Mutant Positive Advanced Glioma
4:01pm
8-K
EX-99.2
pf3h4up8ka16q
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.1
dj3fsqxuamlwz3tf9l9
22 Nov 19
Other Events
5:01pm
8-K
EX-99.1
j63tizuy
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.2
ivgx5 luhm0gfe47o
3 Dec 18
Other Events
4:03pm
8-K
EX-99.1
w9tg6n0kvtvz
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
8-K
EX-99.2
y7bn3yj2hbt
11 Jun 21
Other Events
7:24am
8-K
EX-99.1
cih5qu5tt3pps9ihjd
16 Oct 15
Regulation FD Disclosure
12:00am
8-K
EX-99.3
imculs 3op
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
mqvc693moylg9cpnyc
26 Jan 21
Other Events
4:14pm
8-K
EX-99.3
tts1dc
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.1
albjq84fknvhusbu
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am